Welch Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Welch Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$529K	Hold	849	–	–	0.02%	183
2026 Q1	$656K	Buy	849 +500	+143%	+$383K	0.02%	152
2025 Q4	$269K	Sell	349 -9	-3%	-$6.11K	0.01%	253
2025 Q3	$201K	Buy	+358	New	+$202K	0.01%	287
2025 Q2	–	Sell	-345	Closed	-$220K	–	289
2025 Q1	$220K	Sell	345 -23	-6%	-$15.8K	0.01%	235
2024 Q4	$259K	Buy	368 +8	+2%	+$6.71K	0.01%	221
2024 Q3	$378K	Buy	360 +150	+71%	+$167K	0.02%	176
2024 Q2	$221K	Sell	210 -203	-49%	-$197K	0.01%	233
2024 Q1	$398K	Buy	413 +3	+0.7%	+$2.85K	0.02%	145
2023 Q4	$360K	Buy	410 +140	+52%	+$115K	0.02%	157
2023 Q3	$222K	Buy	+270	New	+$212K	0.01%	191

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Welch Group's REGN Position: Q2 2026 in Review

Welch Group held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 849 shares worth $529K. The position accounts for 0.02% of the portfolio, ranked #183.

Welch Group first reported a position in REGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $656K in Q1 2026. 454 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Welch Group held 849 shares of Regeneron Pharmaceuticals worth $529K as of Q2 2026.
Welch Group left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.02% of Welch Group's portfolio in Q2 2026, its #183 holding.
Welch Group first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Welch Group's Regeneron Pharmaceuticals position peaked at $656K in Q1 2026.
454 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Welch Group's 13F filing for Q2 2026, filed 23 Jul 2026.